Patients with malignant renal tumors (renal cell carcinoma) scheduled for elective unilateral laparoscopic nephrectomy (including partial or radical nephrectomy)
Conditions
Interventions
Liposomal bupivacaine group (LB group):Liposomal bupivacaine thoracic paravertebral nerve block
Ropivacaine group (RO group):Ropivacaine thoracic paravertebral nerve block
Sponsors
He'nan Cancer Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged 40–75 years; gender unrestricted. 2.ASA physical status classification I–III; 3.Planned procedure: Unilateral laparoscopic nephrectomy (including LPN/LRN) under elective general anesthesia. 4.BMI 20–28.0 kg/m²; 5.Possess normal communication skills and the ability to understand and complete the VAS and QoR-15 scale assessments. 6.Voluntarily participate in the study and sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1.Allergy to amide-type local anesthetics; 2.Infection, abscess, or severe skin lesions at the puncture site; coagulation abnormalities (INR > 1.5, platelet count = 30 mg morphine equivalents/day) or took central-acting analgesics such as gabapentin or pregabalin on a long-term basis within the 3 months prior to surgery. 4.Patients with drug or alcohol dependence; 5.Severe spinal deformity and a history of extensive thoracic spine surgery predict TPVB failure. 6.A history of prior open surgery in the ipsilateral lumbar or upper abdominal region (such as ipsilateral nephrectomy, open hepatobiliary/pancreatic surgery, etc.) that may significantly alter local anatomy or affect postoperative pain and the quality of recovery. 7.Central or peripheral nervous system disorders affecting pain perception or assessment—such as a history of stroke with residual significant motor or sensory deficits, Parkinson's disease, poorly controlled epilepsy, significant cognitive impairment or dementia, or peripheral neuropathy affecting sensory assessment in the dermatomes of the operative side—or an inability to cooperate with QoR/VAS assessments. 8.Patients with severe hepatic impairment (Child-Pugh class C) or severe renal impairment (creatinine clearance <15 mL/min and not undergoing regular dialysis); 9.Women who are pregnant or breastfeeding, or those planning a pregnancy without using effective contraceptive measures; 10.Individuals who have participated in other clinical trials recently (within the past 3 months).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of recovery score at 24 hours postoperatively (total QoR-15 score); | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient satisfaction with postoperative analgesia at 48 hours;Quality of Recovery-15 (QoR-15) score at 48 and 72 hours postoperatively;Incidence of postoperative adverse events within 72 hours;Cumulative opioid consumption at 24 and 48 hours postoperatively;Postoperative functional recovery parameters (time to first ambulation, time to first flatus, and length of postoperative hospital stay);Visual Analogue Scale (VAS) pain scores at rest and during coughing at 1, 6, 12, 24, 48, and 72 hours postoperatively;Patient-controlled analgesia requirements and rescue analgesic use within 72 hours after surgery; | — |
Countries
China
Contacts
Public ContactYi Zhou
He'nan Cancer Hospital
Outcome results
None listed